PeerVoice Endocrinology & Metabolic Disorders Video

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

http://www.peervoice.com

Eine durchschnittliche Folge dieses Podcasts dauert 20m. Bisher sind 30 Folge(n) erschienen. Alle 2 Monate erscheint eine Folge dieses Podcasts
subscribe
share



 
  • 1
  • 2
  •    
  • 3
  • >
share





 2019-05-16  17m
 
 

A Closer Look at Safety of Glucose-Lowering Therapy


A Closer Look at Safety of Glucose-Lowering Therapy


share





 2019-02-28  21m
 
 

Improving Outcomes in Type 2 Diabetes: Focus on Cardiovascular and Renal Safety


Improving Outcomes in Type 2 Diabetes: Focus on Cardiovascular and Renal Safety


share





 2018-11-07  1h13m
 
 

Ticking All the Boxes: A Multidisciplinary Approach to Hidradenitis Suppurativa


Ticking All the Boxes: A Multidisciplinary Approach to Hidradenitis Suppurativa


share





 2018-10-18  1h10m
 
 

Considering the Possibility of Psoriatic Arthritis in Patients With Psoriasis


Considering the Possibility of Psoriatic Arthritis in Patients With Psoriasis


share





 2018-04-26  17m
 
 

Cardiovascular and Renal Safety in Type 2 Diabetes: What Clinicians Need to Know


Go online to www.peervoice.com/UVD860 to view the entire programme with slides.


share





 2018-04-21  21m
 
 

Modern Management of Patients With Rheumatic Diseases: What Pharmacists Need to Know About Biologic Therapies


Go online to www.peervoice.com/XQA860 to view the entire programme with slides.


share





 2018-03-15  17m
 
 

SGLT2 Inhibitors: From A1C to Cardiac and Renal Outcomes


SGLT2 Inhibitors: From A1C to Cardiac and Renal Outcomes


share





 2018-01-17  17m
 
 
share





 2018-01-04  22m
 
 
share





 2017-10-11  21m
 
 
  • 1
  • 2
  •    
  • 3
  • >